Want to see TELA full AI Analyst Report?
Top Page
TELA Bio
(NASDAQ:TELA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$1.00
▲(42.86% Upside)
Action:Reiterated
Date:10/06/26
The score is held down primarily by weak financial performance (large losses, cash burn, negative equity, and elevated debt). Technicals are moderately supportive with improving longer-term trend and neutral momentum, but valuation remains constrained by ongoing losses and no dividend. Earnings-call updates and corporate events add incremental positives (cost actions, margin strength, FDA clearance, Nasdaq compliance) but are outweighed by guidance withdrawal and near-term execution/liquidity risks.
Positive Factors
Revenue scale and gross margins
Multi-year revenue expansion shows meaningful commercialization progress, while consistently strong gross margins indicate the products retain attractive economics. Together, these traits provide a foundation for operating leverage if TELA can convert market adoption into sufficient scale.
Negative Factors
Persistent operating losses and cash burn
Sustained negative operating and free cash flow means the current business is not yet self-funding. Continued losses can require additional financing or sharper cost reductions, limiting strategic flexibility and increasing execution pressure while the company pursues growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scale and gross margins
Multi-year revenue expansion shows meaningful commercialization progress, while consistently strong gross margins indicate the products retain attractive economics. Together, these traits provide a foundation for operating leverage if TELA can convert market adoption into sufficient scale.
Read all positive factors
TELA Bio (TELA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.46M
Dividend YieldN/A
Average Volume (3M)302.64K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue Growth6.09%
EPS Growth30.65%
CountryUS
Employees218
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.77
Shares Outstanding45,143,410
10 Day Avg. Volume212,683
30 Day Avg. Volume302,641
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue0.87
Enterprise Value/Gross Profit1.28
Enterprise Value/Ebitda-2.09
Forecast
1Y Price Target
$1.75Price Target Upside150.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$79.64M
TELA Bio Business Overview & Revenue Model
Company Description
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provide...
How the Company Makes Money
TELA Bio primarily makes money by selling its surgical implants and related surgical instruments to healthcare providers for use in soft-tissue reconstruction procedures. The core revenue stream is product revenue generated from the sale of reinfo...
TELA Bio Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Negative
The call presented a mix of operational positives (12% unit growth, strong international performance, LIQUIFIX momentum, improved gross margin and leadership changes) but was dominated by near-term commercial execution issues: a revenue miss (-4% YoY), a sharp PRS revenue decline (~24%), ASP/mix pressure, extended sales ramp timelines, higher interest expense, and withdrawal of full-year guidance. Management outlined concrete remediation steps (leadership upgrades, training programs, market access improvements, cost reductions) and expressed confidence in second-half recovery, but near-term financial and competitive headwinds are material.Positive Updates
OviTex Unit Volume Growth
Global OviTex unit volume increased 12% year-over-year to ~5.78k units (Q2 2026 vs 5.18k in Q2 2025), indicating procedural share gains despite mix headwinds.
Negative Updates
Total Revenue Miss and Decline
Total revenue for Q2 2026 was $19.3M, down ~4% year-over-year from $20.2M and below company expectations.
Read all updates
Q2-2026 Updates
Positive
Negative
OviTex Unit Volume Growth
Global OviTex unit volume increased 12% year-over-year to ~5.78k units (Q2 2026 vs 5.18k in Q2 2025), indicating procedural share gains despite mix headwinds.
Read all positive updates
Company Guidance
Management withdrew prior full‑year revenue guidance and said it will finalize a plan to meaningfully reduce costs and extend the cash runway (cash $30.4M) — with fundraising a last resort — while remaining optimistic that the second half will be stronger as PRS recovers with retraining and a longer rep ramp (now 9–12 months vs ~6 months prior). Q2 metrics cited: revenue $19.3M (‑4% YoY), OviTex units 5,780 (+12% YoY) and OviTex revenue $13.3M (+0.6%), OviTex PRS revenue $5.5M (vs $7.3M; PRS unit volume down ~23%), international sales $3.8M (+26%), other/LIQUIFIX $0.5M (+39%); gross profit $13.9M and gross margin 72% (70% prior); total operating expense $23.2M (S&M $16.4M, G&A $4.1M, R&D $2.7M); loss from operations $9.3M (vs $9.1M) and net loss $11.3M, with interest expense $2.1M (vs $1.2M prior); management will update guidance after the cost‑alignment plan is finalized.TELA Bio Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.91M | 80.28M | 69.30M | 58.45M | 41.42M | 29.46M |
| Gross Profit | 54.19M | 54.34M | 46.49M | 40.11M | 27.04M | 18.81M |
| EBITDA | -33.12M | -32.35M | -31.68M | -40.63M | -39.06M | -29.14M |
| Net Income | -41.18M | -38.83M | -37.84M | -46.66M | -44.30M | -33.28M |
Balance Sheet | ||||||
| Total Assets | 59.74M | 81.42M | 87.33M | 78.05M | 67.86M | 62.54M |
| Cash, Cash Equivalents and Short-Term Investments | 30.42M | 50.84M | 52.67M | 46.73M | 42.02M | 43.93M |
| Total Debt | 56.61M | 55.65M | 43.06M | 42.77M | 41.46M | 31.49M |
| Total Liabilities | 75.60M | 75.11M | 58.87M | 59.17M | 53.55M | 42.45M |
| Stockholders Equity | -15.87M | 6.31M | 28.46M | 18.88M | 14.30M | 20.10M |
Cash Flow | ||||||
| Free Cash Flow | -31.62M | -28.67M | -42.58M | -41.47M | -42.62M | -31.06M |
| Operating Cash Flow | -31.14M | -28.22M | -41.59M | -40.86M | -40.75M | -30.43M |
| Investing Cash Flow | 933.00K | 846.00K | 4.45M | -599.00K | -1.87M | -627.00K |
| Financing Cash Flow | 25.56M | 25.75M | 43.06M | 46.27M | 40.85M | 585.00K |
TELA Bio Technical Analysis
Positive
0.70
Price Trends
0.91
Positive
0.87
Positive
0.87
Positive
Market Momentum
0.08
Positive
50.35
Neutral
6.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TELA, the sentiment is Positive. The current price of 0.7 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 0.91, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 50.35 is Neutral, neither overbought nor oversold. The STOCH value of 6.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TELA.
TELA Bio Risk Analysis
TELA Bio disclosed 78 risk factors in its most recent earnings report. TELA Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TELA Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $78.60M | -1.63 | -96.66% | ― | -3.43% | 19.16% | |
50 Neutral | $51.46M | -1.48 | 1248.13% | ― | 6.09% | 30.65% | |
48 Neutral | $5.38M | -0.23 | -174.26% | ― | 41.62% | 20.47% | |
47 Neutral | $49.06M | -3.11 | -34.09% | ― | -53.40% | -1719.88% | |
47 Neutral | $10.20M | -1.22 | -126.45% | ― | -1.67% | 7.34% | |
45 Neutral | $12.76M | -0.69 | -445.14% | ― | 8.64% | -61.01% |
* Healthcare Sector Average
TELA
TELA Bio
1.09
-0.48
-30.57%
CTSO
Cytosorbents
3.96
-14.95
-79.05%
SRTS
Sensus Healthcare
2.97
-0.58
-16.34%
NMTC
NeuroOne Medical Technologies
1.13
-5.23
-82.23%
LUNG
Pulmonx
1.78
0.05
2.89%
ICCM
Icecure Medical
1.27
-28.73
-95.77%
TELA Bio Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
TELA Bio Regains Nasdaq Compliance, Securing Listing Status
Positive
Oct 6, 2026
On October 5, 2026, TELA Bio, Inc. disclosed that it had received notification from The Nasdaq Stock Market LLC that the company had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market under...
Business Operations and StrategyProduct-Related Announcements
TELA Bio gains FDA clearance for Liora scaffold
Positive
Oct 5, 2026
On October 5, 2026, TELA Bio announced it had received U.S. Food and Drug Administration 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. Liora is the first implant to be fully d...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
TELA Bio gains short-term relief on loan covenants
Positive
Sep 29, 2026
On September 28, 2026, TELA Bio, Inc. entered into a Limited Consent to its existing Credit Agreement and Guaranty with Perceptive Credit Holdings V, LP as administrative and collateral agent and the lenders constituting the required lenders. Unde...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
TELA Bio Faces Nasdaq Delisting, Plans Reverse Split
Negative
Sep 18, 2026
On March 17, 2026, TELA Bio, Inc. was notified by Nasdaq that its common stock no longer met the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, and after failing to regain compliance by the September 14, 202...
Business Operations and StrategyExecutive/Board Changes
TELA Bio Implements Workforce Cuts and Leadership Changes
Negative
Aug 31, 2026
On August 28, 2026, TELA Bio’s board approved a workforce reduction plan cutting headcount by about 20%, from 201 to 160 employees, as part of a strategic initiative to lower operating expenses and preserve capital for driving product sales ...
Business Operations and StrategyExecutive/Board Changes
TELA Bio appoints Heather Getz as new CEO
Neutral
Aug 4, 2026
On August 3, 2026, TELA Bio’s board removed Antony Koblish as chief executive officer and principal executive officer and accepted his resignation as a director, effective that day, treating his departure as a termination without cause and i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.